AstraZeneca Total Liabilities 2010-2024 | AZN

AstraZeneca total liabilities from 2010 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
  • AstraZeneca total liabilities for the quarter ending June 30, 2024 were $64.742B, a 9.5% increase year-over-year.
  • AstraZeneca total liabilities for 2023 were $61.953B, a 4.25% increase from 2022.
  • AstraZeneca total liabilities for 2022 were $59.425B, a 10.07% decline from 2021.
  • AstraZeneca total liabilities for 2021 were $66.076B, a 29.33% increase from 2020.
AstraZeneca Annual Total Liabilities
(Millions of US $)
2023 $61,953
2022 $59,425
2021 $66,076
2020 $51,091
2019 $46,781
2018 $46,607
2017 $46,712
2016 $45,857
2015 $41,547
2014 $38,949
2013 $32,646
2012 $29,588
2011 $29,364
2010 $32,717
2009 $34,099
AstraZeneca Quarterly Total Liabilities
(Millions of US $)
2024-06-30 $64,742
2024-03-31 $64,792
2023-12-31 $61,953
2023-09-30 $58,865
2023-06-30 $59,127
2023-03-31 $60,876
2022-12-31 $59,425
2022-09-30 $59,031
2022-06-30 $60,628
2022-03-31 $63,914
2021-12-31 $66,076
2021-09-30 $67,309
2021-06-30 $57,948
2021-03-31 $50,480
2020-12-31 $51,091
2020-09-30 $50,494
2020-06-30 $46,271
2020-03-31 $44,995
2019-12-31 $46,781
2019-09-30 $45,237
2019-06-30 $46,818
2019-03-31 $49,026
2018-12-31 $46,607
2018-09-30 $47,906
2018-06-30 $47,072
2018-03-31 $48,708
2017-12-31 $46,712
2017-09-30 $49,140
2017-06-30 $49,707
2017-03-31 $46,180
2016-12-31 $45,857
2016-09-30 $48,310
2016-06-30 $49,029
2016-03-31 $47,681
2015-12-31 $41,547
2015-09-30 $36,750
2015-06-30 $36,870
2015-03-31 $36,745
2014-12-31 $38,949
2014-09-30 $35,698
2014-06-30 $36,487
2014-03-31 $37,913
2013-12-31 $32,646
2013-09-30 $30,674
2013-06-30 $30,575
2013-03-31 $29,841
2012-12-31 $29,588
2012-09-30 $30,193
2012-06-30 $29,156
2012-03-31 $29,048
2011-12-31 $29,364
2011-09-30 $28,422
2011-06-30 $29,591
2011-03-31 $31,987
2010-12-31 $32,717
2010-09-30 $34,078
2010-06-30 $32,382
2010-03-31 $33,187
2009-12-31 $34,099
2009-09-30 $32,346
2009-06-30 $32,258
2009-03-31 $30,986
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $221.444B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $777.423B 80.52
Novo Nordisk (NVO) Denmark $502.334B 38.34
Johnson & Johnson (JNJ) United States $385.533B 15.64
AbbVie (ABBV) United States $359.539B 18.93
Merck (MRK) United States $258.042B 17.12
Novartis AG (NVS) Switzerland $223.511B 14.86
Pfizer (PFE) United States $159.177B 10.89
Sanofi (SNY) $135.190B 12.25
Innoviva (INVA) United States $1.205B 6.69